Opioid addiction has cast a shadow over the U.S. But pharma stock Indivior Pharmaceuticals is eyeing a fresh entry as profits soar.
Stock Spotlight
This Pharma Stock Eyes Entry As Opioid Addiction Specialist's Profits Surge 108%
Licensing
12:41 PM ET 07/31/2026
The scourge of opioid addiction has cast a pall over the U.S. But pharma stock Indivior Pharmaceuticals (INDV), which helps sufferers get to grips with the condition, is eyeing a fresh entry as the company's profit soars. The Virginia-based company aims to treat and advance the understanding of Opioid Use Disorder, or OUD. One of its key treatments is Sublocade,…
Supernus, Indivior merge to create CNS-focused company and expand BD opportunities
Supernus, Individor merge to beef up brain drug portfolio
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Reven
Supernus, Indivior to merge and form CNS-focused drugmaker
Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis
Biogen flips '26 guidance from expected decline to sales increase
More medical and healthcare stocks are joining lists of top stocks to buy, including Indivior. Its products help decrease opioid…
Two growing companies, Supernus Pharmaceuticals and Indivior Pharmaceuticals, have
The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster…
Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $125 million in synergies.
Supernus and Indivior agree to an all-stock merger creating a $2.2B CNS biopharma led by CEO Jack Khattar, closing Q4 2026.
The stock of Omada, an Eli Lilly partner, has soared more than 118% in recent months, moving up the right side of a new base.
